clobazam (Onfi) + Initial conversion and titration + Conversion schedule - Week 1 + Conversion schedule - Week 2 + Conversion schedule - Week 3
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Refractory Epilepsy
Conditions
Refractory Epilepsy
Trial Timeline
Feb 1, 2013 → Sep 1, 2017
NCT ID
NCT01932502About clobazam (Onfi) + Initial conversion and titration + Conversion schedule - Week 1 + Conversion schedule - Week 2 + Conversion schedule - Week 3
clobazam (Onfi) + Initial conversion and titration + Conversion schedule - Week 1 + Conversion schedule - Week 2 + Conversion schedule - Week 3 is a approved stage product being developed by Lundbeck for Refractory Epilepsy. The current trial status is unknown. This product is registered under clinical trial identifier NCT01932502. Target conditions include Refractory Epilepsy.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Epilepsy were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01932502 | Approved | UNKNOWN |
Competing Products
20 competing products in Refractory Epilepsy